ecancer
Avatar

ASCO® 2023 Insights: "Dr. Roy Herbst on ADAURA Trial OS Analysis of Adjuvant Osimertinib in Patients With Resected EGFRm Stage IB–IIIA NSCLC"

By ecancer FEATURING Roy Herbst
By ecancer FEATURING Roy Herbst
0 views
June 14, 2023
Comments 0
Login to view comments. Click here to Login

Featured Video

06:27
Johnson & Johnson

Challenges to Navigate in Locally Advanced or Metastatic EGFR+ NSCLC

Feat. M. Socinski, D. Waterhouse

Featured Video

08:44
Johnson & Johnson

Management and Proactive Care of Adverse Events Associated with Loca…

Feat. J. Sabari, A. Spira

Recommended

AUTOPLAY
35:40
Balazs Halmos

Year in Review: Lung Cancer

17:20
Total Health

2024 Intervention Selection & Sequencing in Early Stage NSCLC

Feat. J. Porter
18:47
Total Health

Updates in the Management of NSCLC: Systemic Therapy Year in Review

Feat. W. Iams
11:07
Insights from 2023 ASCO® Annual Meeting

ASCO® 2023 Insights: "ADAURA Trial Key Learnings & Clinical…

Feat. J. West
36:14
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

Feat. B. Halmos
16:10
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

Feat. L. Raez
17:34
ecancer

Recent NSCLC Updates Including PAPILLON, CHECKMATE 77T, and KEYNOTE-…

Feat. L. Raez
16:57
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Precision Medicine Highlights: LAURA and CROWN Trials (NS…

Feat. V. Subbiah
14:49
Vivek Subbiah

Year in Review: Precision Medicine

26:21
Memorial Sloan Kettering Cancer Center

NSCLC & Targeted Therapy: A Brief Overview and Update in the Met…

Feat. M. Hwang
19:33
ecancer

ASCO® 2024 Lung Cancer Roundtable: Advances in NSCLC

Feat. E. Felip, A. Spira, A. Passaro, A. Addeo
06:47
UCSF School of Medicine

Tumor-Agnostic Efficacy & Safety of Selpercatinib in RET Fusion+…

Feat. H. Kang
09:40
John Conibear

PACIFIC Trial 5-Year OS Data: Clinical Implications in NSCLC

21:24
Chul Kim

ADCs and Bispecific Inhibitors in NSCLC

08:30
Insights from 2023 ESMO Annual Meeting

PAPILLON Study - Amivantamab + Chemo vs. Chemo as 1L Treatment in EG…

Feat. N. Girard
05:02
GRACE

Targeted Therapies in Lung Cancer 2023: Biomarkers in NSCLC

Feat. A. Desai
11:45
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "KRYSTAL-12 Study - Adagrasib vs. Docetaxe…

Feat. T. Mok
20:27
Yale Cancer Center

Progress in the Treatment of NSCLC

Feat. R. Herbst
18:09
MSKCC 2nd Annual Symposium on Advanced Therapeutics for Brain Metastasis

The Changing Prognosis of Lung Cancer Brain Metastases

Feat. S. Goldberg
23:32
2023 West Oncology Conference

2023 Updates on Neoadjuvant and Adjuvant NSCLC

Feat. M. Johnson